Third Harmonic Bio Announces Third Quarter 2024 Financial Results
Third Harmonic Bio, Inc. (THRD)
Company Research
Source: GlobeNewswire
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the third quarter September 30, 2024. “As the Phase 1 clinical trial of our development candidate THB335 continues toward an anticipated data readout in the first quarter of 2025, we are also making excellent progress in preparing to move efficiently into a Phase 2 clinical trial in chronic spontaneous urticaria,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio. “We believe an oral small molecule has the potential to be the optimal approach to targeting KIT for the treatment of urticaria and o
Show less
Read more
Impact Snapshot
Event Time:
THRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
THRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
THRD alerts
High impacting Third Harmonic Bio, Inc. news events
Weekly update
A roundup of the hottest topics
THRD
News
- Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade [Yahoo! Finance]Yahoo! Finance
- Third Harmonic Bio to Participate in Upcoming Investor Conferences in NovemberGlobeNewswire
- Third Harmonic Bio Announces Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Third Harmonic Bio (NASDAQ:THRD) Is In A Strong Position To Grow Its Business [Yahoo! Finance]Yahoo! Finance
- Third Harmonic Bio to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswire
THRD
Earnings
- 5/15/24 - Beat
THRD
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form SC
- 11/12/24 - Form 4
- THRD's page on the SEC website